/PMVP
PMVP Stock - PMV Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$1.24+0.81%
+$0.01 (+0.81%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.38
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1593.5%upside
Target: $21.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PMVP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.23 – $1.25
TARGET (TP)$21.00
STOP LOSS$1.14
RISK/REWARD1:197.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.64
52W High$1.84
52W Low$0.81
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,144,000 | $-1,257,000 | $-650,000 | $-1,281,000 | $-318,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-85,448,000 | $-80,132,000 | $-77,040,000 | $-58,293,000 | $-34,942,000 |
| Net Income | $-58,709,000 | $-68,960,000 | $-73,317,000 | $-57,846,000 | $-34,440,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.14 | $-1.44 | $-1.61 | $-1.28 | $-2.40 |
Company Overview
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$6
Average Target
↑ 383.9% Upside
Now
$5
Low
$6
Average
$7
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 8th 2024 | Oppenheimer | Upgrade | Outperform | $6 |
| May 13th 2024 | Craig Hallum | Initiation | Buy | $6 |
| April 12th 2024 | Jefferies | Initiation | Buy | $5 |
| December 27th 2023 | Ladenburg Thalmann | Initiation | Buy | $7 |
Earnings History & Surprises
PMVPBeat Rate
61%
Last 18 quarters
Avg Surprise
+8.7%
EPS vs Estimate
Beats / Misses
11/5
2 met exactly
Latest EPS
$-0.40
Q4 2025
EPS Surprise History
Q1 24
+20.5%
$-0.31vs$-0.39
Q2 24
+14.3%
$-0.30vs$-0.35
Q3 24
+94.1%
$-0.02vs$-0.34
Q4 24
-5.7%
$-0.37vs$-0.35
Q1 25
-18.4%
$-0.45vs$-0.38
Q2 25
+8.1%
$-0.34vs$-0.37
Q3 25
-5.1%
$-0.41vs$-0.39
Q4 25
0.0%
$-0.40vs$-0.40
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.40 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.40 | $-0.40 | 0.0% | = MET |
Q3 2025 | Aug 7, 2025 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q2 2025 | May 9, 2025 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.38 | $-0.45 | -18.4% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.34 | $-0.02 | +94.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.39 | $-0.31 | +20.5% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.45 | $-0.34 | +24.4% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.47 | $-0.38 | +19.1% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.48 | $-0.42 | +12.5% | ✓ BEAT |
Q1 2023 | Mar 1, 2023 | $-0.44 | $-0.43 | +2.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.42 | $-0.41 | +2.4% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.35 | $-0.41 | -17.1% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.31 | $-0.33 | -6.5% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.29 | $-0.29 | 0.0% | = MET |
Latest News
PMV Pharma Q3 EPS $(0.40), Inline
➖ NeutralBenzinga•Nov 12, 2025, 01:12 PM
PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses
📈 PositiveBenzinga•Oct 24, 2025, 03:44 PM
PMV Pharmaceuticals To Present Rezatapopt Pivotal Phase 2 Initial Analysis And Natural History Study Results
📈 PositiveBenzinga•Oct 13, 2025, 08:05 PM
PMV Pharma Announces Interim Data From Phase 2 Pivotal Portion Of PYNNACLE Clinical Trial; Plans To Submit NDA For Platinum Resistant/Refractory Ovarian Cancer By End Of Q1 2027
📈 PositiveBenzinga•Sep 10, 2025, 11:11 AM
Frequently Asked Questions about PMVP
What is PMVP's current stock price?
PMV Pharmaceuticals, Inc. (PMVP) is currently trading at $1.24 per share. The stock has moved +0.81% today.
What is the analyst price target for PMVP?
The average analyst price target for PMVP is $21.00, based on 1 analyst.
What sector is PMV Pharmaceuticals, Inc. in?
PMV Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PMVP's market cap?
PMV Pharmaceuticals, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does PMVP pay dividends?
No, PMV Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
BMEA
Biomea Fusion, Inc.
$1.40
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
Explore stocks similar to PMVP for comparison